Skip to content

Lymph node dissection in prostatectomy

When to remove the pelvic nodes, how the nomograms help and what the trials show.

Dr. Petronio Melo, urologistA reference in prostate cancer
CRM-SP 157.598 · RQE 70.275
Reviewed by Dr. Petronio Melo on November 20, 2026
Book a consultation
Drawing of the pelvis with the bladder, the prostate, the iliac arteries and veins on both sides and the lymph nodes along them, some of them highlighted
On this page

Quick answer

Pelvic lymph node dissection is the removal of the lymph nodes in the pelvis during radical prostatectomy. It is not done in every patient: the indication depends on the chance that the cancer has reached the nodes, estimated with nomograms.1 In my practice, I use the Briganti nomograms, with a 7% cut-off in the 2019 version for men who had an MRI-targeted biopsy,4 and I follow the European guideline. When I remove the nodes, the dissection is always extended, as the guideline recommends.2 The main purpose of the dissection is to find out whether the cancer reached the nodes, which guides treatment after surgery.1

What pelvic lymph node dissection is

In robotic surgery, lymph node dissection is done through the same incisions as the prostatectomy. The European guideline recommends that, when the nodes are removed, the dissection be extended. It includes the nodes over the external iliac artery and vein, the nodes in the obturator fossa above and below the obturator nerve, and those on both sides of the internal iliac artery.1,2

A limited dissection, of the obturator fossa only, finds fewer nodes and misses more cases of cancer in the nodes.1 That is why, in my practice, it has no indication: when the nodes are removed, I always perform an extended dissection.

When to remove the nodes: the Briganti nomograms

The nomograms most used for this decision were developed by Alberto Briganti's team in Milan. Each version has a proposed cut-off: below it, the dissection can be skipped.

NomogramFor whomCut-offWhat the study showed
Briganti 2012Standard biopsy. Uses the PSA, the rectal exam, the Gleason grade and the percentage of positive cores.5%In 588 patients, 65.5% would avoid the dissection, and 1.5% of those who would go without it had positive nodes.3
Briganti 2019MRI-targeted biopsy. Uses the PSA, the stage and size of the lesion on MRI and the results of the targeted and systematic biopsies.7%In 497 patients, 57% would avoid the dissection, and 1.6% of those who would go without it had positive nodes.4 In another 487 patients from 6 centers, 56% would avoid the dissection.5

In the 6-center validation, the 2019 nomogram was more accurate than the 2012 and 2017 versions and the Memorial Sloan Kettering calculator from New York.5

The 2026 European guideline does not set a number. It explains that every cut-off is a trade-off between the risk of leaving a cancerous node behind and the extra operating time and complications.1

What about PSMA PET?

The European guideline recommends PSMA PET for staging high-risk cancer and suggests it for unfavorable intermediate risk. It is more sensitive than MRI and CT for finding cancerous nodes.1

Even so, PSMA PET does not see deposits smaller than about 5 mm, and an extended dissection can find them.1 An international study showed that adding the PSMA PET result to the nomograms improves the estimate. There are already specific models for men with a negative PSMA PET.1

What the randomized trials show

  • University of São Paulo trial: 300 intermediate- or high-risk patients, operated on at the São Paulo State Cancer Institute, were randomized to limited or extended dissection. The extended dissection found more cancerous nodes but did not reduce PSA recurrence in early follow-up. In patients with ISUP grade group 3 to 5 on biopsy, there was a signal of benefit that still needs confirmation.6
  • Memorial Sloan Kettering trial: 1,440 patients, with no difference in PSA recurrence at 3.1 years.7 In the 2025 update, at 5.4 years of follow-up, extended dissection reduced distant metastases by about 25%.8

Based on these data, the European guideline treats extended dissection as a staging procedure: it shows more precisely whether the cancer reached the nodes, and that result guides the next steps.1 The same guideline advises against using frozen sections of the nodes during surgery to decide whether to continue or abandon the prostatectomy.2

Complications

Lymph node dissection adds operating time and some complications of its own, according to the European guideline:1

  • Lymphocele: a collection of lymph fluid in the pelvis. In recent randomized trials, symptomatic lymphocele occurred in 0.9% to 9.7% of patients. Larger ones may need drainage.
  • Thrombosis and embolism: node removal raises the risk. In the series analyzed, deep vein thrombosis occurred in 2.8% and pulmonary embolism in 2.1%.
  • Pelvic hematoma in 2.6% and leg swelling (lymphedema) in 1.5%.

In the Memorial Sloan Kettering trial, grade 2 and 3 complications were similar in both groups: 7.3% with limited and 6.4% with extended dissection, with no grade 4 or 5 complications.7 The robotic radical prostatectomy page explains the operation as a whole.

If a node is positive

The prostatectomy pathology report states how many nodes were examined and how many had cancer: pN0 means none, and pN1 means at least one.

With pN1, the European guideline discusses three paths: hormone therapy, hormone therapy with radiotherapy, or PSA monitoring alone when there are up to 2 positive nodes and the PSA stays undetectable. In a study of 209 patients with 1 or 2 positive nodes, 37% remained free of metastases and salvage treatment after 5 years.2

How I approach it

Before surgery, I calculate with you the chance that the cancer has reached the nodes. I use the Briganti nomograms, the 2019 version with a 7% cut-off for men who had an MRI-targeted biopsy,4 and I follow the European guideline.1 PSMA PET, when indicated, is part of the same discussion. When lymph node dissection is indicated, it is always extended, done robotically during the same operation.

After surgery, I go over the report with you, including how many nodes were examined and how many had cancer. For my PhD at the University of São Paulo Medical School, I studied slides of prostates removed by radical prostatectomy, and that reading is part of the consultation. The PSA is followed as explained on the PSA after prostatectomy page.

If you live outside São Paulo or want a second opinion on the indication, the first consultation can be online, in English, with your tests sent in advance.

Frequently asked questions

Does every prostatectomy need a lymph node dissection?

No. Lymph node dissection is indicated when the chance that the cancer has reached the nodes is higher. That chance is estimated with nomograms, such as the Briganti nomograms, using the PSA, the rectal exam, the biopsy and the MRI.1,4 With the 2019 Briganti nomogram and a 7% cut-off, 57% of dissections would be avoided, and only 1.6% of the patients who would go without one had positive nodes.4

What is the cut-off of the Briganti nomogram?

It depends on the version. In the 2012 nomogram, built for standard biopsy, the proposed cut-off was 5%.3 In the 2019 nomogram, built for men who had an MRI-targeted biopsy, the proposed cut-off was 7%, confirmed in 6 other centers.4,5 The European guideline notes that every cut-off is a trade-off between the risk of leaving a cancerous node behind and the extra operating time and complications.1

Does removing the lymph nodes improve cure rates?

In the two largest randomized trials, extended dissection did not reduce PSA recurrence compared with limited dissection.6,7 In the update of the larger trial, with 1,432 patients, extended dissection reduced distant metastases at 5.4 years of follow-up.8 Its clearest value is staging, because knowing whether the cancer reached the nodes guides treatment after surgery.1

What is a lymphocele?

It is a collection of lymph fluid in the pelvis, where the nodes were removed. It is the most common complication of lymph node dissection. In recent randomized trials, symptomatic lymphocele occurred in 0.9% to 9.7% of patients. Many need no treatment, and larger ones can be drained.1

My PSMA PET showed nothing in the nodes. Do I still need a lymph node dissection?

You may. PSMA PET is more sensitive than MRI and CT for the nodes, but it does not see deposits smaller than about 5 mm.1 That is why the European guideline still uses nomograms, and there are already models for men with a negative PSMA PET.1

Who performs robotic prostatectomy with lymph node dissection in São Paulo?

I do. I am a urologist and robotic surgeon in São Paulo, Brazil, with a PhD from the University of São Paulo Medical School and more than 500 robotic operations. To decide whether to remove the nodes, I use the Briganti nomograms and follow the European guideline. When I remove them, the dissection is always extended. The first consultation can be online, in English.

References

  1. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer: diagnostic evaluation. European Association of Urology; 2026. EAU
  2. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer: treatment. European Association of Urology; 2026. EAU
  3. Briganti A, Larcher A, Abdollah F, et al. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol. 2012;61(3):480-487. PubMed
  4. Gandaglia G, Ploussard G, Valerio M, et al. A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies. Eur Urol. 2019;75(3):506-514. PubMed
  5. Gandaglia G, Martini A, Ploussard G, et al. External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection. Eur Urol. 2020;78(2):138-142. PubMed
  6. Lestingi JFP, Guglielmetti GB, Trinh QD, et al. Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial. Eur Urol. 2021;79(5):595-604. PubMed
  7. Touijer KA, Sjoberg DD, Benfante N, et al. Limited versus Extended Pelvic Lymph Node Dissection for Prostate Cancer: A Randomized Clinical Trial. Eur Urol Oncol. 2021;4(4):532-539. PubMed
  8. Touijer KA, Vertosick EA, Sjoberg DD, et al. Pelvic Lymph Node Dissection in Prostate Cancer: Update from a Randomized Clinical Trial of Limited Versus Extended Dissection. Eur Urol. 2025;87(2):253-260. PubMed

Would you like to talk about your case?

In the consultation, I go over your tests and your priorities.

Book a consultation

Related guides